Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12310934
Methods of treatment of spontaneous preterm birth
granted -
US 12312357
PRMT5 inhibiting compounds and uses thereof
granted -
US 12312589
RNA-nanostructured double robots and methods of use thereof
granted -
WO 2025108443
COMPOSÉS HÉTÉROCYCLIQUES ET COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT CORRESPONDANTES
granted -
WO 2025111408
COMPOSÉS POUR LE TRAITEMENT DE L'AMYOTROPHIE SPINALE ET DE LA MALADIE DE HUNTINGTON
granted -
WO 2025111409
COMPOSÉS HÉTÉROCYCLIQUES DE FORMULE (I) DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'AMYOTROPHIE SPINALE PAR MODULATION DE L'ÉPISSAGE DE SMN2
granted -
WO 2025111258
COMPOSITIONS DE SÉROTYPE A DE NEUROTOXINE DE CLOSTRIDIUM BOTULINUM ET PROCÉDÉS DE FILTRATION AMÉLIORÉS
granted -
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
granted -
US 12319740
Methods for production of tissue resident memory-like T cells and use thereof
granted -
US 12319929
Compositions and methods for the treatment of Parkinson's disease
granted -
US 12319703
Macrocyclic fused pyrazoles as Mcl-1 inhibitors
granted -
US 12319724
IL2 agonists and methods of use thereof
granted -
US 12318401
Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy
granted -
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12317874
Method of using a genetically modified mouse that expresses human albumin
granted -
US 12318386
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
granted -
US 12318364
Isoflavonoid compositions and methods for the treatment of cancer
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12318418
Modified adenoviruses
granted -
US 12318426
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12319651
Crystalline forms and methods of producing crystalline forms of a compound
granted -
US 12319657
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 12318413
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
granted -
US 12319693
Crystalline forms of CFTR modulators
granted -
US 12319728
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12319738
Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
granted -
US 12319729
Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same
granted -
US 12318356
Use of cannabinoids in the treatment of epilepsy
granted -
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12318375
Method of treatment with tradipitant
granted -
US 12319737
NK engager molecules and methods of use thereof
granted -
US 12319711
Spherical nucleic acids with tailored and active protein coronae
granted -
US 12319744
Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12319752
Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
granted -
US 12319916
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
granted -
US 12319743
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
US 12318439
Attenuating viral mutations in protein genes
granted -
US 12319684
Agonists of the apelin receptor and methods of use thereof
granted -
US 12319708
Agonists of peroxisome proliferator-activated receptor alpha (PPARα) and methods of use
granted -
US 12319940
Methods for purification of arylsulfatase A
granted -
EP 4563165
PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE
granted -
WO 2025114430
COMPOSITION À LIBÉRATION MODIFIÉE
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.